Summary

Sell, $15.85 target: the $54.97 price needs 14.6% growth forever

InitiationBy Penmark Team
RKLBSell$15.85-71%
Page 1 of 27
Equity research | Initiation of coverage | United States
Space and defense | Coverage: Initiated | Published 10 November 2026, 18:00 ET
Penmark Team | research@penmarkresearch.com
Rocket Lab Corporation (Nasdaq: RKLB)

Sell, $15.85 target: the $54.97 price needs 14.6% growth forever

Rating
Initiation
Sell
12-month target
$15.85
Price, 10 Nov*
$54.97
Price return**
−71.2%
Total return
−71.2%
Bull case
$28.73
Bear case
$9.23
*Intraday, after Q3 release; close $62.71. **Rating = price return to target, excl. dividends: Buy above +10%, Hold −10% to +10%, Sell below −10%.

We initiate at Sell with a $15.85 target, a price return of −71.2%. Rocket Lab sells Electron launches and satellites and is building Neutron. The market pays 44.0x sales; our probability-weighted value is $13.83 a share, and the $28.73 bull target is 47.7% below the price.

  • Neutron is a 2027 event. First flight is no earlier than 2027 after four date resets; we model 18 launches a year, and even 50 a year values the stock at $16.63.
  • Space Systems is priced for +37.3pp extra growth a year. We model +30% in FY27E on a $1.71bn backlog: $11.11 standalone.
  • Cash and investments of $4.70bn are $6.71 a share. Weighted diluted shares rise from 530.7m in FY25A to 700.9m in FY27E; Iridium adds $1.69.

What the market is missing. Near-term numbers agree: FY27E revenue is 0.4% below consensus. The price needs 14.6% terminal growth, or a 4.5% cost of equity, below the 4.9% risk-free rate.

Catalysts. Q4 results (Feb 2027), Neutron tank qualification (Q1 2027), first flight (2027), Iridium close (mid-2027).

Valuation and target. DCF plus Iridium at 12.5x gives a $12.80 base; bear $8.05 (30%) and bull $25.06 (20%) weight to $13.83, rolled to $15.85. EV/sales gives $16.88.

Risks. Against our Sell: Neutron at 50 a year (+$3.83), Iridium at 16.2x (+$2.50). None nears the price.

Exhibit 1: Revenue grows 63% in FY26E; EPS turns positive in FY28E, at 478x earnings
Year to 31 Dec, US$FY24AFY25AFY26EFY27EFY28E
Revenue ($m)4366029821,3251,734
Growth y/y–38.0%63.2%34.8%30.9%
EBITDA ($m)−156−185−180−68132
Margin−35.8%−30.7%−18.3%−5.1%7.6%
Net income ($m)−190−198−196−4181
EPS ($)−0.38−0.37−0.31−0.060.12
Growth y/yn.m.n.m.n.m.n.m.n.m.
Free cash flow ($m)−116−322−2417248
At $54.97FY24AFY25AFY26EFY27EFY28E
P/En.m.n.m.n.m.n.m.478x
EV/EBITDAn.m.n.m.n.m.n.m.256x
P/B100.7x22.4x6.6x6.6x6.4x
FCF yield−0.3%−0.8%−0.6%0.0%0.6%
Dividend yield0.0%0.0%0.0%0.0%0.0%
ROE−49.7%−11.5%−3.4%−0.7%1.3%
Net debt / EBITDANet cashNet cashNet cashNet cashNet cash
P/E at our $15.85 targetn.m.n.m.n.m.n.m.138x

Source: Company filings (A); Penmark Research model (E); Yahoo Finance. Right: multiples at the $54.97 model price on diluted shares; only the last row is at target. n.m. = negative. Shaded = estimates.

Base value is $12.80; even the 12-month bull target of $28.73 is 47.7% below the $54.97 price

Exhibit 3: Every case is below the $54.97 price: bull $28.73, base $14.67, bear $9.23
$0$50$100$150Jan-26Jul-26Jan-27Jul-27ActualEstimatesPrice $54.97Bull $28.73 (−48%)Base $14.67 (−73%)Bear $9.23 (−83%)Target $15.85 (−71%)

Source: Yahoo Finance; Penmark Research model. Case values rolled 12 months at the 14.65% cost of equity

Scenarios and price target basis
Bull$25.06−54.4%20% prob.

Neutron $70m, 55% margin, 50 a year; Space Systems +45% fading to 6%; Iridium 16.2x. Target $28.73 (−47.7%).

Base$12.80−76.7%50% prob.

Neutron flies 2027, $60m, 45% margin, 18 a year; Space Systems +30% fading to 4%; Iridium 12.5x. Target $14.67 (−73.3%).

Bear$8.05−85.3%30% prob.

Neutron slips to 2028, $50m, 30% margin, 8 a year; Space Systems +18%; Iridium 10.0x. Target $9.23 (−83.2%).

Price target (probability-weighted)$15.85−71.2% price return = Sell
Price / weighted value4.0x$54.97 vs $13.83
Exhibit 4: Loss narrows to $41m in FY27E, then profit of $81m in FY28E
Income statement, US$mFY24AFY25AFY26EFY27EFY28E
Revenue4366029821,3251,734
Gross profit116207349424560
EBITDA−156−185−180−68132
EBIT−190−229−260−16711
Net interest, other037112674
Income tax1−28704
Net income, reported−190−198−196−4181
Memo: SBC5771849395
Exhibit 5: Free cash flow turns positive in FY27E at $7m, helped by deposits
Cash flow, US$mFY24AFY25AFY26EFY27EFY28E
Operating cash flow−49−166−117167398
o/w customer deposits–−2119771143
Capex−67−156−124−160−150
Free cash flow−116−322−2417248
FCF excl. deposits–−301−439−63104
Memo: acquisitions0−132−44––
Memo: Iridium cash–––−2,737–
Year-end cash4191,1044,6821,9532,201
Exhibit 6: Net cash of $4.66bn in FY26E falls to $1.94bn after Iridium
Balance sheet, US$mFY24AFY25AFY26EFY27EFY28E
Cash, investments4191,1044,6821,9532,201
PP&E and intangibles253544735796825
Goodwill71206301301301
Iridium, at cost–––2,7372,737
Customer deposits216195393464607
Debt, finance leases416169171717
Net cash29354,6651,9352,183
Equity3821,7225,7995,8506,026
Exhibit 7: Weighted diluted shares rise 41% from FY24A to FY27E to 700.9m
Per share and KPIsFY24AFY25AFY26EFY27EFY28E
Diluted shares (m)496531642701701
EPS, reported ($)−0.38−0.37−0.31−0.060.12
Dividend per share ($)0.000.000.000.000.00
FCF/share ($)−0.23−0.61−0.380.010.35
Book value/share ($)0.773.249.038.358.60
Electron+HASTE launches1621253033
Neutron launches00013
SS revenue ($m)–4037439661,207

Source: Company filings (A); Penmark Research model (E); company filings (FY24A balance sheet). Scenario % = today’s value vs the $54.97 price; 12-month targets in text. Statements standalone; Iridium at cost from mid-2027. SBC = stock-based compensation; SS = Space Systems. Shaded = estimates.

Margins turn positive in FY28E, and our FY27E EPS is 35% above a consensus set before the print

Exhibit 8: EBITDA margin rises from −35.8% to +7.6% by FY28E as opex growth slows
Growth, margins (%)FY24AFY25AFY26EFY27EFY28E
Growth y/y
Sales78.3%38.0%63.2%34.8%30.9%
EBITDAn.m.n.m.n.m.n.m.n.m.
EBITn.m.n.m.n.m.n.m.n.m.
EPSn.m.n.m.n.m.n.m.n.m.
DPS–––––
Margins
Gross margin26.6%34.4%35.5%32.0%32.3%
EBITDA margin−35.8%−30.7%−18.3%−5.1%7.6%
EBIT margin−43.5%−38.0%−26.4%−12.6%0.6%
FCF margin−26.6%−53.5%−24.6%0.6%14.3%
EBITDA / net interestn.m.n.m.n.m.n.m.1.8x
Capex / sales15.4%26.0%12.6%12.1%8.6%
Exhibit 9: Returns stay negative to FY27E; at $54.97 FCF yield is 0.0% in FY27E
Ratios and valuationFY24AFY25AFY26EFY27EFY28E
Returns and leverage
ROE−49.7%−11.5%−3.4%−0.7%1.3%
ROA−16.8%−9.1%−3.1%−0.6%1.2%
ROCE−23.8%−12.1%−4.5%−2.8%0.2%
Net debt / equity−1%−54%−80%−33%−36%
Net debt / EBITDAn.m.n.m.n.m.n.m.n.m.
Valuation at $54.97
P/En.m.n.m.n.m.n.m.478x
EV/EBITDAn.m.n.m.n.m.n.m.256x
FCF yield−0.3%−0.8%−0.6%0.0%0.6%
Dividend yield0.0%0.0%0.0%0.0%0.0%
P/E at our $15.85 targetn.m.n.m.n.m.n.m.138x

Source: Company filings (A); Penmark Research model (E); company filings (FY24A balance sheet). ROE and ROA use year-end equity and total assets net of operating payables. Multiples at the $54.97 model price on 700.9m diluted shares, EV $33.8bn. n.m. = not meaningful (negative). No dividend is paid.

Exhibit 10: We are 0.4% below consensus on FY27E revenue and 35.1% above it on EPS
Ours vs consensusQ4 FY26EFY26EFY27E
Revenue ($m)
Penmark estimate2809821,325
Consensus2669591,330
Prior-year period180602982
Diff. vs consensus+5.1%+2.4%−0.4%
Growth y/y (Penmark)+55.9%+63.2%+34.8%
EPS ($)
Penmark estimate−0.03−0.31−0.06
Consensus−0.05−0.27−0.09
Prior-year period–−0.37−0.31
Diff. vs consensus+37%−13.0%+35.1%
Growth y/y (Penmark)n.m.n.m.n.m.

Source: Company filings; Penmark Research model (E). Consensus: S&P Global via StockAnalysis, Yahoo Finance, before the 9 Nov print; Q4 EPS from Yahoo Finance. Yahoo’s later mean is $1,352m revenue and −$0.09 EPS for FY27E.

Exhibit 11: Revenue grows 63% in FY26E and 35% in FY27E, 2.4% above and 0.4% below consensus
Consensus$0m$500m$1,000m$1,500m$2,000mFY24AFY25AFY26EFY27EFY28EActualEstimates$436m$602m$982m$1,325m$1,734m

Source: Company filings (A); Penmark Research model (E); consensus: S&P Global via StockAnalysis, Yahoo Finance, pre-print

What it means for valueNear-term numbers are not where we disagree: revenue is within 2.4% of consensus for FY26E and FY27E; Q4 is 5.1% above because we use the guide midpoint. EPS differs because we credit $126m of FY27E interest on $4.7bn of cash; consensus predates the print. Cash earns about 3.8% (Q4 guide $45m interest), but is already counted in value at $6.71 a share.

Four dated events test the thesis; RKLB trades at 11x the peer sales multiple

Exhibit 12: RKLB trades at 11x the peer median EV/sales for 8.4pp more growth
MetricRKLBPeer medianDifference
Valuation
EV / TTM sales44.0x3.9x+1,020%
EV/sales per point of growth0.84x0.15x+458%
Market value ($bn)38.52.0+1,870%
Growth and returns
Revenue growth, TTM52.5%44.1%+8.4pp
Revenue, TTM ($m)769426+80%
Operating margin, TTM−29.1%−27.5%−1.6pp

Source: Penmark Research model, 9 Nov 2026. Median of 5 peers (RDW, LUNR, PL, KTOS, VOYG); TTM to Jun 2026; % for multiples, pp for ratios.

Exhibit 13: Four dated catalysts, next 6-9 months
  • Feb 2027Q4 FY26 results: guide $270-290m; we sit at $280m, 5.1% above consensus $266m. FY27 launch growth above 20% tested.
  • Q1 2027Neutron Stage 1 tank qualification. A further slip is our bear 1: −$0.27 a share.
  • 2027Neutron first flight. We model one revenue flight in FY27E; success lifts the ramp, worth +$0.30 for +2 flights a year.
  • Mid-2027Iridium close, about 44m RKLB shares issued. Base assumes 90% probability and 12.5x OEBITDA.

Source: Q3 FY26 call; Penmark Research model.

Exhibit 14: The largest risk to our Sell is Neutron at 50 a year, +$3.83; Iridium ranges from −$1.66 to +$2.50
  • Neutron slips again. Ramp moves a year right. Likelihood 40%; −$0.27/share.
  • Iridium re-rates down. 10.0x OEBITDA after EMSS renewal. Likelihood 30%; −$1.66/share.
  • Iridium at the 16.2x deal multiple (against our Sell). Likelihood 25%; +$2.50/share.
  • Neutron at 50 launches a year (against our Sell). Market-implied path; +$3.83/share.
The rating changes only ifthe price falls below $17.62 or our target rises above $49.47 (both Hold). The largest single item, the 50-a-year Neutron path at +$3.83, still leaves value at $16.63.

Source: Penmark Research model, 10 Nov 2026.

Exhibit 15: RKLB trades at 43.7x trailing sales, in line with its 44.5x two-year average
0x25x50x75x100x125x150xJul-24Jan-25Jul-25Jan-26Jul-26Mean 45x; bands ±1σ, ±2σ44x

Source: Yahoo Finance prices; company-reported revenue and diluted shares; Penmark calculation, May 2024 to 10 Nov 2026

Exhibit 16: RKLB sells at 44.0x sales against a 3.9x peer median at similar growth
0x20x40x60x0255075100125EV / TTM salesRevenue growth, TTM to Jun 2026 (%)RKLBRDWLUNRPLKTOSVOYGR² 0.13, n=5

Source: Penmark Research model, prices 9 Nov 2026; company filings

How to read Exhibits 15 and 16Market value to trailing sales has averaged 44.5x over two years, so RKLB is not cheap against its own history. Against five peers growth explains little (R-squared 0.13) and RKLB sits far above the line. SpaceX is private and cannot be plotted.
PART 1 · SUMMARY · 3 THE THESIS IN CHARTS

RKLB trades with the space sector, not its own numbers: the sector ETF explains 66% of weekly moves

Exhibit 17: RKLB tracks the space ETF: weekly return correlation 0.81, R-squared 0.66
RKLBUFO space ETF, rebased to RKLB$25$50$75$100$125$150Jan-26Apr-26Jul-26Oct-26$55$63

Source: Yahoo Finance weekly closes, 7 Nov 2025 to 10 Nov 2026; regression on 106 weekly returns, 1 Nov 2024 to 6 Nov 2026

Exhibit 18: Backlog is up 3.3x since 1Q25 and the share price 3.9x on quarter-end closes: correlation 0.62
Backlog ($m)Share price ($) (right)$0m$1,000m$2,000m$3,000m$4,000m$0$20$40$60$80$100$1201Q252Q253Q254Q251Q262Q263Q26

Source: Company releases (backlog); Yahoo Finance quarter-end closes, 1Q25 to 3Q26 (3Q26 close $69.68 on 30 Sep 2026)

Exhibit 19: Space Systems is 80% of Q3 FY26 revenue at $214.8m, up 88% on Q3 FY25
Space SystemsLaunch Services$0m$100m$200m$300m1Q252Q253Q254Q251Q262Q263Q26$268m

Source: Company 10-Q segment notes and Q3 FY26 call ($m)

Exhibit 20: FY27E EPS of -$0.06 is 35% above consensus of -$0.09; FY26E is 13% below
PenmarkConsensusFY26E EPSFY27E EPS−$0.31−$0.27−$0.09−$0.06

Source: Penmark Research model (E); consensus: Yahoo Finance and S&P Global via StockAnalysis, pre-print

Exhibit 21: No method gets near $54.97: values run from $8.05 to $25.06
Scenarios, bear to bullEV/sales cross-checkCost of equity +/-1ptThesis range$0$20$40$60$8$25$15$17$12$13$12$15Price $55Target $16

Source: Penmark Research model, 10 Nov 2026

Exhibit 22: The Iridium multiple moves value most, by $4.16 across its range; Neutron price moves $0.74
Iridium EV/OEBITDA 10.0x/ 16.2xSS gross margin 32% /base 36%Neutron price $50m /$70mNeutron launches +1yrdelay / +2 a yearSS growth FY27E -10pp /FY28-30E +5ppElectron launches +3 ayearBase $12.80−$1.66+$2.50−$0.66−$0.37+$0.37−$0.27+$0.30−$0.13+$0.21+$0.04

Source: Penmark Research model, 10 Nov 2026

PART 1 · SUMMARY · 3 THE THESIS IN CHARTS

Over 12 months sales growth added $30.49 a share, but dilution and a lower multiple took $27.15

Exhibit 23: Over 12 months sales growth added $30.49 a share; dilution and de-rating took $27.15
$0$20$40$60$80$1007 Nov 2025RevenuegrowthSharedilutionMultiple10 Nov 2026$51.64+$30.49−$15.55−$11.60$54.97

Source: Yahoo Finance; TTM revenue ($554.5m to $881.9m) and weighted diluted shares (Q3 FY25 528.7m to Q3 FY26 652.3m); Penmark calculation

Exhibit 24: The Street low target of $58 is 3.7x our $15.85 target
Penmark target $16Street low $58Street median $102Share price (model) $55Street mean $100Street high $150

Source: MarketBeat, S&P Global via StockAnalysis, 6-10 Nov 2026; Penmark Research model

Street against PenmarkEvery Street target is above the price and above our bull case of $28.73. The lowest, Piper Sandler at $58 (cut from $83 on 10 Nov), is 5.5% above the price. Closing the gap needs the market path on all four debates, not one.
Exhibit 25: The strongest evidence against our Sell, and why it does not change the rating
Bull claimEvidenceOur answer
Demand is provenBacklog $3.57bn, +52% on the prior quarter; 16 Neutron missions booked, several at $70mAgreed; priced at 25.5x FY27E sales. Demand is not the debate, timing and value are.
Management beats its guideRevenue above or inside the guide in 8 of 8 quarters; Q3 GAAP gross margin 33.6% vs 29-31% guideAgreed; a $10m (4%) quarterly beat does not close a $42 gap.
Raising equity at $65 helps holdersQ3 ATM raised about $2.4bn, far above model value; it lifted value per share by $1.58Agreed, and in our number; weighted diluted shares rise 41% from FY24A to FY27E.
The Street is Buy18 of 22 Buy, none Sell, mean target $100.25, low $58Street targets sit above the price in every case; none models the 14.6% terminal growth the price needs.
The stock closed at $62.71The 10 Nov close was 14% above our intraday $54.97At $62.71 the return to target is −74.7%; the rating does not change.

Source: Q3 FY26 release and call, 9 Nov 2026; MarketBeat; Yahoo Finance; Penmark Research model

Exhibit 26: To justify $54.97 the model needs 14.6% terminal growth, or a cost of equity of 4.5%
14.6%model 3.0%Implied terminal growth4.5%model 14.7%; risk-free 4.9%Implied cost of equity+37.3ppevery year FY27E-FY40ESpace Systems growth uplift25.5x4.8x at our targetEV/sales FY27E at price

Source: Penmark Research model, 10 Nov 2026

What would change the ratingA Hold needs a price return above −10%: a target above $49.47 at today’s price, or a price below $17.62 at our target. Our 12-month bull target, $28.73, is 47.7% below the price; the price implies 14.6% terminal growth. We would revisit the target if Neutron flies and the market path of 50 launches a year looks achievable, worth $3.83 a share in our model.
Why we rate it SellEvery scenario, including the bull case, lands below the price. The rating rests on valuation, not on one event, and no single catalyst moves value by more than about $3 a share.
PART 1 · SUMMARY · 4 KEY DEBATES

Four debates are worth $14.07 a share at the market view; $28.10 of the $42.17 gap is left unexplained

Each debate is priced alone: the market view replaces ours and every other input stays at base. Together they lift $12.80 to $26.87, still half the price. The stock needs more than winning any one debate.

Exhibit 27: Four debates, each tied to a driver in section 9
DebateMarket viewPenmark viewEvidenceWhat changes our viewResolvesValue gap
1 Discount rateSector beta 0.95 (cost of equity 8.9%)Beta 2.31, cost of equity 14.7%Beta regression; peer betas 1.9-3.3Neutron flies and RKLB beta falls toward 1.5First Neutron flight, 2027$5.95
2 Neutron cadence50 flights a year by FY34E18 a year; 1-3-5 rampFour date resets; no flight date; 16 missions bookedFlight 1 in H1 2027 and a ramp ahead of 1-3-5First flight, FY28 manifest, 2027$3.83
3 Space Systems growthBull path: +45% FY27E fading to 6%+30% FY27E fading to 4% by FY40EBacklog $1.71bn; CFO 20% long-run barQ4 print and SDA, Golden Dome awards add backlogQ4 FY26 results, Feb 2027$1.78
4 Iridium value16.2x deal multiple on CY27E OEBITDA12.5x undisturbed, Aireon-consistentDeal EV $8.0bn on FY25 OEBITDA of $495m; EMSS renewal 2027Close with PNT and direct-to-device growthClose, mid-2027$2.50

Source: Penmark Research model, 10 Nov 2026; Q3 FY26 call

Exhibit 28: Our four debates explain $14.07 of the $42.17 gap between value and price; $28.10 is unexplained
$0$20$40$60Base value1 Discount rate2 Neutroncadence3 Space Systemsgrowth4 Iridium valueValue at marketviewsUnexplainedPrice$12.80+$5.95+$3.83+$1.78+$2.50$26.87+$28.10$54.97

Source: Penmark Research model: each debate priced at the market view, others at base, 10 Nov 2026

DateEventDebateWhat it tests
Feb 2027Q4 FY26 results3Space Systems conversion, FY27 launch growth above 20%
Q1 2027Neutron Stage 1 tank qualification2Whether a 2027 first flight holds
2027Neutron first flight1, 2Reuse, cadence and the right discount rate
Mid-2027Iridium close4Regulatory approvals; about 44m RKLB shares issued

Source: Penmark Research model; Q3 FY26 call, 9 Nov 2026

How the debates map to the thesis chaptersDebate 2 (Neutron cadence) is chapter 10, debate 3 (Space Systems growth) is chapter 11, and debates 1 and 4 (discount rate, Iridium) are chapter 12 on what the price implies. Each chapter ends in dated signposts drawn from the table above.
PART 2 · THE BUSINESS · 5 THE STORY

A rocket company that earns 80% of its revenue from satellites is valued at $38.5bn

Rocket Lab flies small rockets and builds spacecraft for governments. The twist is that the rocket it has not yet flown, Neutron, carries most of the value in the share price.

20 yrsFounded 2006
$3.57bnBacklog, 30 Sep 2026
$602mRevenue, FY25A
3,259Employees, Q3 FY26
$38.5bnMarket cap, diluted

The scene

On 9 November 2026 Peter Beck, Rocket Lab’s founder, told investors there is still no first-flight date for Neutron, the rocket the company has promised for years. “We haven’t provided guidance on that just yet because we need to get through the Stage 1 tank,” he said. The same call reported revenue of $267.8m, above the top of guidance. Rocket Lab, founded in New Zealand in 2006 and now headquartered in Long Beach, California, flies small rockets and builds satellites, mostly for governments.

What it actually does

Launch Services sells rides on Electron, a small rocket with 75 successful missions through 2025, and on HASTE, a suborbital version. Space Systems builds satellites, solar panels and optics. Neutron, a reusable rocket for up to 13,000kg to low orbit, is not yet flying.

How the money comes in

Customers pay by contract, and often in advance: contract liabilities were $423.6m at 30 September 2026. In FY25, Space Systems brought in $402.8m (67% of revenue) and Launch Services $199.0m (33%). Launch is flights times price: 21 launches at about $9.5m each. Space Systems is projects; it was $214.8m in Q3, 80% of the quarter. Of each FY25 dollar, 34 cents was gross profit, spending took 72 cents and free cash flow was −53 cents.

Where the story turns

On 28 June Rocket Lab agreed to buy Iridium, the satellite-phone operator, at an enterprise value of $8.0bn. It sold about $2.4bn of new shares in Q3 to pay for it, lifting cash to $4.45bn ($4.70bn with investments). On 14 October it moved Neutron’s first flight into 2027; the shares fell 20.8% in three sessions.

Why it works, and why it might not

It works because demand is real: backlog is $3.57bn, up 52% on the prior quarter, with 117 launches booked and 16 Neutron missions, several at a $70m base price. It might not because the price already assumes a SpaceX-scale outcome: to justify $54.97 our model needs 14.6% growth in perpetuity. That is chapter 12.

44.0xEV to trailing-year sales
Rocket Lab trades at 44.0x sales; the peer median is 3.9x.Source: Penmark Research model, 9 Nov 2026; trailing 12 months to Jun 2026. Peers: RDW, LUNR, PL, KTOS, VOYG.
1 FINDS IT
117launches in the backlog
2 BUYS IT
1 launchone Electron or HASTE flight, under contract
3 PAYS
$9.6mrevenue per launch in FY26E, with deposits up front
4 COMPANY KEEPS
34%of FY25 revenue was gross profit; spending took 72%
Why the story matters for the stockThe market is paying for Neutron and Space Systems at scale, not for Electron. Chapter 10 tests Neutron’s timeline and chapter 11 Space Systems growth.
PART 2 · THE BUSINESS · 5 HOW THE COMPANY MAKES MONEY

Space Systems earns 67% of revenue and Launch 33%; every dollar of FY25A gross profit was spent twice over on research and overhead

Exhibit 29: Operating costs were $436m on $207m of gross profit in FY25A: Rocket Lab spends its cash on growth
Space Systems$403mLaunch Services$199mRevenue$602mCost of revenue$395mGross profit$207mOperating loss (fundedfrom cash)$229mOperating costs$436mR&D$271mSG&A$165m

Source: Company 10-K; Penmark Research model, FY25A ($m)

Exhibit 30: Backlog of $3.57bn is 4.0x trailing-year revenue and Q3 beat the top of the guide
$3.57bn+52% on Q2; 32.9%converts in 12 monthsBacklog, 30 Sep 2026117Electron and HASTELaunches in backlog$214.8mbacklog $1.71bnSpace Systems Q3revenue33.6%guide 29-31%GAAP gross margin, Q33,2592,602 at Q3 FY25Headcount, Q3 FY26

Source: Q3 FY26 release and call, 9 Nov 2026; company 10-Q

Exhibit 31: FY27E revenue of $1,324.6m is 30 Electron launches, one Neutron flight and Space Systems growth of 30%
Electron and HASTE$298.7mNeutron$60.0mLaunch Services$358.7m, 27%FY26E base$743.0mGrowth+30%Space Systems$965.9m, 73%Revenue FY27E$1,324.6m, +34.8%

Source: Penmark Research model; highlighted boxes are the drivers we forecast

Exhibit 32: Launch grows from $199m to $527m by FY28E as Neutron adds $185m; Space Systems triples to $1.2bn
Segment build, US$mFY25AFY26EFY27EFY28EFY30E
Launch Services revenue199239359527950
Electron and HASTE launches2125303338
Neutron launches00138
Space Systems revenue4037439661,2071,768
Space Systems growth–84.4%30.0%25.0%20.0%
Group gross margin–35.5%32.0%32.3%36.9%

Source: Penmark Research model; FY25A from company filings

Who pays, and whenSpace Systems customers pay under fixed-price and cost-plus contracts for spacecraft and components, often with deposits: contract liabilities were $423.6m at 30 Sep 2026. Launch customers pay per mission. Revenue per Electron and HASTE launch is $9.6m in FY26E and rises 4% a year in the model.
What one dollar becomesOf each FY25A revenue dollar, 34 cents was gross profit, 72 cents went to research and administration, and free cash flow was −53 cents. Mix is the lever: Neutron at 45% gross margin lifts group margin from 32% in FY27E to 39% by FY33E.
PART 2 · THE BUSINESS · 5 REVENUE, COSTS AND CASH

Gross profit of $424m in FY27E still trails operating costs of $591m; Neutron closes the gap by FY30E

Exhibit 33: In FY27E gross profit of $424m is still smaller than operating costs of $591m
Space Systems$966mElectron and HASTE$299mNeutron$60mRevenue$1,325mCost of revenue$900mGross profit$424mOperating loss (fundedfrom cash)$167mOperating costs$591mR&D$342mSG&A$249m

Source: Penmark Research model, FY27E ($m)

Exhibit 34: Space Systems is 73% of FY27E revenue; Neutron reaches 19% of FY30E sales
Space SystemsElectron and HASTENeutron$0m$1,000m$2,000m$3,000mFY25AFY26EFY27EFY28EFY29EFY30EActualEstimates

Source: Penmark Research model ($m)

Exhibit 35: Iridium nets $1.88bn to Rocket Lab holders after $2.9bn of cash and $2.0bn of debt
$0$2,000$4,000$6,000$8,000Iridium EV,12.5xNet debtassumedCash paidCostsNet value$6,965−$2,041−$2,941−$100$1,882

Source: Penmark Research model ($m); EV on CY27E OEBITDA of $558.8m at 12.46x

Exhibit 36: Cash falls from $4.68bn to $1.95bn in FY27E when the Iridium cash is paid
$0m$1,000m$2,000m$3,000m$4,000m$5,000mFY25AFY26EFY27EFY28EActualEstimates$1,104m$4,682m$1,953m$2,201m

Source: Company filings (A); Penmark Research model (E)

Cash against profitCompany-definition free cash flow of −$241m in FY26E and +$7m in FY27E includes customer deposits. Excluding them it is −$439m and −$63m; the model values cash flow without deposits and deducts the $423.6m balance in the equity bridge.
PART 2 · THE BUSINESS · 6 THE MARKET AND 7 COMPETITIVE POSITION

Launch is a $12.4bn market and Rocket Lab flew 5.5% of the world’s 329 orbital attempts in 2025

Demand is not the constraint; capacity and price are. Commercial launch revenue rose from $9.3bn in 2024 to $12.4bn in 2025, inside a $429bn space economy. SpaceX flew 165 of 329 attempts.

Exhibit 37: Launch is a $12.4bn market inside a $429bn space economy; Rocket Lab earns in two layers
LaunchSpaceX, China, RocketLab, ULA$12.4bn commercial 2025Satellite manufacturingSpace Systems: platforms,solar, optics$20.4bn industry 2025Satellite servicesIridium (pending),operators$105.0bn 2025Ground equipmentTerminals, user devices$165.2bn 2025Government demandSDA, NSSL, Golden Dome$24.4bn Golden Dome2025 lawWhere Rocket Lab books revenue today

Source: Industry totals: Satellite Industry Association and launch-market sources, 2025; company filings

Exhibit 38: Rocket Lab flew 18 of 329 orbital attempts in 2025, 5.5% of the world total
SpaceX FalconChinaOtherRocket Lab ElectronRussiaArianespaceULAStarship tests16592191817765

Source: Public launch logs compiled by Penmark Research, calendar 2025; Rocket Lab flew 21 including 3 suborbital HASTE

Exhibit 39: SpaceX holds 28 of 54 NSSL Lane 2 missions; Rocket Lab holds none
SpaceXULABlue OriginNSSL Lane 2 missions28197

Source: US Space Force NSSL Phase 3 Lane 2 allocation, 54 missions, up to $13.68bn

Defense demand is the near-term pullSDA Tranche 3 was about $3.5bn for 72 satellites in December 2025; Rocket Lab’s potential share was $805m for 18. NSSL Lane 1’s ceiling grew from $5.6bn to $17bn; Rocket Lab can bid after Neutron’s first success.
Pricing sets the ceilingFalcon 9’s published price reached $74m in February 2026, from $70m in 2025. Neutron’s base price rose from $55m to $70m; our base case uses $60m blended in FY27E.
What it means for valueNeutron would join Falcon 9 and New Glenn as a reusable rocket; its 16-mission backlog supports the $70m base price. The risk is timing: a one-year ramp delay costs $0.27 a share in our model, a $50m price $0.37.
Exhibit 40: Falcon 9 and New Glenn recover boosters; Neutron has no flight date
RocketStatus, Nov 2026ReusePrice evidence
Falcon 9 (SpaceX)Operational; 165 flights in 2025Booster reused$74m published price, Feb 2026
Neutron (Rocket Lab)No date; first flight no earlier than 2027Reusable first stage by design$70m base; 16 missions booked
Vulcan (ULA)Return to flight targeted 13 Nov 2026ExpendableAbout $214m per government mission
Ariane 6 (Arianespace)Operational; 7 flights in 2025ExpendableEUR 82.07m for one Sentinel-1D mission
New Glenn (Blue Origin)Has flownBooster recoveredNot published

Source: Company statements, launch-provider and US Space Force announcements, Nov 2026; Penmark Research compilation. Prices are published or reported figures, not quotes

PART 2 · THE BUSINESS · 8 MANAGEMENT, GOVERNANCE AND CAPITAL ALLOCATION

Shareholders funded $3.9bn of equity in nine months; share count is up 3.0x since FY21

Exhibit 41: Rocket Lab burned $0.6bn of operating cash and spent $0.8bn on capex and deals since FY21
Operating cash flowCapexAcquisitions−$200m−$150m−$100m−$50m$0mFY21AFY22AFY23AFY24AFY25A9M26A

Source: Company cash flow statements ($m)

Exhibit 42: Weighted diluted shares rose from 209.9m in FY21 to 629.3m in 9M FY26
0m200m400m600m800mFY21AFY22AFY23AFY24AFY25A9M26A210m466m482m496m531m629m

Source: Company income statements (m); Q3 FY26 ATM raised about $2.4bn gross

Exhibit 43: The founder controls 7.5% of votes and pay has no Neutron or per-share hurdle
AreaFindingWhy it matters
ControlPeter Beck is founder, CEO and Chair; 46.4m shares, 7.5% of votes. All directors and officers hold 8.4%Founder alignment, but no separation of Chair and CEO; Merline Saintil is lead independent director
Board7 directors, 6 independent; three staggered classes; Series A Preferred (about 41m shares, votes 1:1) names a directorStaggered board slows any change of control
PayCEO FY25 pay $6.83m, of which $6.03m time-based stock; no bonus paid; executive awards carry no revenue, EBITDA, Neutron or TSR hurdlePay is not tied to per-share value or to the Neutron date
Related partiesOne item above $120,000: Series A Preferred exchange with Beck’s trust; say-on-pay support about 80% in 2025Limited
InsidersAbout $117m sold in four months to 2 Nov 2026 across 7 insiders; no open-market buys; 99.96% of dollars under 10b5-1 plansPlanned sales, but nobody is buying at $55

Source: FY2025 proxy statement (filed 6 Apr 2026) and Form 4 filings; insider data cover 8 Jul to 2 Nov 2026 only

Exhibit 44: Revenue beat the guide midpoint in all eight quarters, by 4.0% in Q3 FY26
024684Q241Q252Q253Q254Q251Q262Q263Q261.82.17.03.42.74.10.74.0

Source: Company releases and call guidance; Penmark calculation

Capital has gone to growth and acquisitionsGeost ($132.4m cash, Aug 2025), Mynaric (closed 14 Apr 2026, $155.3m including 2.28m shares), Motiv, and Iridium (signed 28 Jun 2026). No buybacks, no dividend; the 2029 convertible notes were extinguished in Q3 FY26 at a $27.3m loss. A $150m conditional Pentagon loan for Neutron (9 Nov 2026) has not closed and is not in our value.
Credible on quarters, not on NeutronRevenue landed above the guided range in 4 of 8 quarters and inside it in 4, never below. Neutron’s first-flight date has been reset four times, from 2024 to H2 2025, 2026, Q4 2026 and now no earlier than 2027.
PART 2 · THE BUSINESS · 9 WHAT MOVES THE STOCK

RKLB trades with the space-sector tape and the Neutron date, not with quarterly results

Four drivers explain the stock’s moves. The sector ETF explains 66% of weekly price variance and results days moved the stock 7.8% on average with almost no link to the revenue surprise (correlation 0.20). Neutron timing is the single topic management hedges most.

Exhibit 45: Four drivers explain the stock; the market pays far more than our model for each
DriverWhat moves the stockEvidenceMarket reaction vs our model valueDebateNext number
A Space-sector tapeWeekly moves track the space ETF (UFO); R² 66% against 21% for the S&P 500Factor regression, return decompositionNot a company value; the ETF beta is 2.0 per 1.0 of sector move1UFO and RKLB weekly moves, ongoing
B Neutron first flightDate slips cut 20.8% in three sessions, 13 to 16 Oct 2026Results-day moves, call Q&A (30 of 112 questions)Close $64.22 to $50.84 (−$13.38); model: one-year delay −$0.272Stage 1 tank qualification, Q1 2027
C Space Systems backlogBacklog +52% on the prior quarter to $3.57bn; Q3 revenue beat the guide by 4.0%Results-day moves (weak), call Q&A (17 of 112)Market view adds $1.78 a share; Q3 print moved the stock −6.6%3Q4 FY26 results, Feb 2027
D Funding and Iridium$2.4bn ATM and 43.6m new shares; deal at 16.2x vs 12.5x undisturbedReturn decomposition, call Q&A (10 of 112)Market view adds $2.50; dilution cost $15.55 over 12 months4Close, mid-2027

Source: Yahoo Finance, company transcripts and filings; Penmark Research calculations and model, Nov 2026. Regressions use 107 weekly returns, 1 Nov 2024 to 10 Nov 2026

Exhibit 46: Eight results days moved the stock 7.8% on average; correlation with the revenue surprise is 0.20
−20−10010203040Q4FY24Q1FY25Q2FY25Q3FY25Q4FY25Q1FY26Q2FY26Q3FY263.3−11.21.1−1.3−4.934.20.0−6.6

Source: Yahoo Finance closes; Q3 FY26 is the 9 Nov close to the 10 Nov intraday model price; surprise vs guide midpoint

Exhibit 47: Over three years the multiple added $42.98 of a $50.64 gain; sales growth added $11.83
$0$20$40$6013 Nov 2023RevenuegrowthSharedilutionMultiple10 Nov 2026$4.33+$11.83−$4.17+$42.98$54.97

Source: Yahoo Finance; TTM revenue ($236.4m to $881.9m) and weighted diluted shares (Q3 FY23 484.0m to Q3 FY26 652.3m); Penmark calculation

Exhibit 48: At the market view every debate is worth more than our base value, but none closes the gap to $54.97
Value at market viewPenmark base value1 Discount rate: beta 0.95 vs 2.312 Neutron cadence: 50 vs 18 a year3 Space Systems growth: bull path vs base4 Iridium value: 16.2x vs 12.5x$12.80$18.75$12.80$16.63$12.80$14.58$12.80$15.30

Source: Penmark Research model, 10 Nov 2026 ($ per share)

PART 2 · THE BUSINESS · 9 WHAT MOVES THE STOCK, CONTINUED

The space ETF explains 66% of price variance; Neutron drew 30 of 112 analyst questions and management hedged on timing

Exhibit 49: The space ETF explains 66% of weekly price variance; the S&P 500 explains 21%
UFO space ETFS&P 500 + UFOS&P 500ITA defense ETF10-year yield66.066.220.920.82.4

Source: Yahoo Finance; OLS on 106 weekly log returns, 1 Nov 2024 to 6 Nov 2026; R-squared in %; Penmark calculation

Exhibit 50: Neutron drew 30 of 112 analyst questions on five calls; management hedged on timing 12 of 18 times
Neutron timingElectron and HASTESpace Systems growthSpace Systems marginsMacro and otherNeutron price and marginIridium and fundingCash flowCompetition1817171414121064

Source: Company call transcripts, Q3 FY25 to Q3 FY26 (5 calls); Penmark classification

A · Debate 1The space-sector tape sets the share price, so the discount rate is the swing factor.

The ETF explains 66% of weekly variance with a coefficient of 2.0. Our model uses RKLB’s own beta of 2.31 (cost of equity 14.7%); valuing it at a sector beta of 0.95 would add $5.95 a share, to $18.75.

Next number: UFO ETF and RKLB weekly returns; a 1% sector move is about 2% for RKLB.

B · Debate 2Neutron’s date moves the stock far more than our model says it should.

Three sessions of 13 to 16 Oct 2026 took the stock from $64.22 to $50.84 (−$13.38, −20.8%). Our model prices a one-year ramp delay at −$0.27, a gap of $13.11 a share. The price needs a faster ramp than the base case.

Next number: Stage 1 tank qualification, Q1 2027. Ours: first flight FY27E, one launch. Consensus: not published. Results days average ±7.8%.

C · Debate 3Space Systems beats are not rewarded: the Q3 print was +4.0% above the guide midpoint and the stock fell 6.6%.

The $1.71bn backlog is 1.47x the $1.17bn of Q4 FY26E plus FY27E Space Systems revenue we model. The market path (+45% fading to 6%) is worth $1.78 a share more than ours.

Next number: Q4 FY26 results, Feb 2027. Ours: revenue $280m. Consensus: $266.4m (+5.1% gap).

D · Debate 4Funding and Iridium decide dilution, and the multiple paid is above the undisturbed one.

The deal is 16.2x FY25 OEBITDA against 12.5x undisturbed. Applying 16.2x to CY27E OEBITDA adds $2.50 a share. The $2.4bn Q3 ATM raised the share count to 639.2m common by 30 Sep 2026.

Next number: Regulatory approvals and close, mid-2027 (90% close probability in our value).

Exhibit 51: Five other factors explain little of the stock’s moves, including the rate and market factors investors assume matter
Other factorResultFinding
10-year Treasury yieldR² 2.4% alone; adds under 1pp to the UFO and S&P modelNo explanatory power
S&P 500R² 21%; coefficient turns negative once UFO is includedSector, not market, is the factor
ITA defense ETFR² 21%Weaker than the space ETF
Revenue surprise vs guideCorrelation 0.20 across eight results daysResults move the stock, but not through the headline beat
Short interest45.3m shares, 1.96 days to cover, little changed since JulyFlat; no trend

Source: Yahoo Finance weekly returns, 107 weekly returns from 1 Nov 2024 to 10 Nov 2026; FINRA short interest; Penmark calculation

PART 3 · THE THESIS · 10 NEUTRON TIMING

Neutron’s date is still unknown, and even a ramp 2.8x our base case is worth only $16.63 a share

THESIS CHAPTER 10 · RESTS ON DRIVER BThe market pays for a fast Neutron ramp; our base case has one flight in FY27E and 18 a year only by FY34E.

What the market believes

Consensus does not publish a Neutron path. At $54.97 the stock needs terminal growth of 14.6% ; even 50 launches a year is worth only $16.63 a share. The 14 Oct slip cost 20.8% in three sessions.

What it is worth

Our base case uses $60m a launch and 45% gross margin; the bull path (50 a year, $70m, 55%) adds $3.83 a share. Bull pricing alone adds $0.37; a one-year delay costs $0.27.

Exhibit 52: Four independent sources agree: demand is real and the date is not
SourceEvidenceRead-through
Company call, 9 Nov 2026No first-flight date; Stage 1 tank qualification ahead; 16 missions booked, eight signed in Q3, several at $70mDemand is real; timing is the risk
Filings and updatesDate reset four times, from 2024 to H2 2025, 2026, Q4 2026, then no earlier than 2027 (8-K, 14 Oct 2026)About three years of slip
Pentagon Office of Strategic Capital, 9 Nov 2026$150m conditional loan to raise Neutron’s flight rate after first launch; not closedSupport for the ramp, after a first flight
Call Q&A, five calls30 of 112 analyst questions on Neutron timing or price; management hedged on timing in 12 of 18Management is least sure on the date

Source: Q3 FY26 call and 8-K; Q&A analysis of five calls, Penmark calculation

Exhibit 53: Neutron’s first flight has moved from H2 2025 to no earlier than 2027; the date has been reset four times since 2024
27 Feb 2025Debut H2 2025Set at FY24 results10 Nov 2025Pad arrival Q1 2026Q3 FY25 call26 Feb 2026Q4 2026After Stage 1 tank failure10 Aug 2026Pad in Q4 2026Q2 FY26 call9 Nov 2026No earlier than 2027No date until tank qualifies

Source: Company results calls and 8-K, 27 Feb 2025 to 9 Nov 2026

Exhibit 54: Base case: Neutron flies once in FY27E and reaches 18 launches a year by FY34E; the bull path needs 50
05101520FY27EFY28EFY29EFY30EFY31EFY32EFY33EFY34E135811141618

Source: Penmark Research model

Exhibit 55: Three dated signposts decide whether the ramp holds
DateSignpostConfirmsBreaks
Q1 2027Stage 1 tank qualifiedDate given for 2027Second tank failure
2027First flight and reuse1-3-5 cadence holdsFlight failure; ramp moves a year, −$0.27
Contracts to 2027Price per launch$70m base holdsPrice falls toward $50m, −$0.37

Source: Penmark Research model; Q3 FY26 call, 9 Nov 2026

PART 3 · THE THESIS · 11 SPACE SYSTEMS GROWTH

Space Systems is 73% of FY27E revenue; a 4-point drift in long-run margin costs more than any growth surprise

THESIS CHAPTER 11 · RESTS ON DRIVER CSpace Systems compounds at 30% in FY27E off a $1.71bn backlog and fades to 4% by FY40E; we are close to consensus on revenue and the price needs far more.

What the market believes

FY27E consensus revenue is $1,330m against our $1,324.6m, a gap of −0.4%. The Q4 FY26 consensus of $266.4m sits 5.1% below our $280m. The market path in debate 3 is +45% in FY27E fading to 6%.

What it is worth

The market path adds $1.78 a share to our $12.80. A long-run margin of 32% instead of 36% costs $0.66; a 20% FY27E growth rate costs $0.13. The base case needs only 68% of the backlog (1.47x cover) to reach FY27E.

Exhibit 56: Three independent sources show orders growing and margins above guide
SourceEvidenceRead-through
Q3 FY26 resultsSpace Systems revenue $214.8m, 80% of the quarter; backlog $3.57bn, +52% on the prior quarter; Space Systems share $1.71bn (48%)Growth is funded by orders
CFO, Q3 callLong-run growth bar about 20%; 32.9% of backlog converts within 12 months; Q4 lower on solar and platformsManagement itself sets the bar below the market’s 45%
Guidance recordRevenue above the range in 4 of 8 quarters, inside in 4, never below; Q3 GAAP gross margin 33.6% vs 29-31% guide, down from 38.2% in Q1Forecasts are conservative; margin is above guide but below Q1

Source: Q3 FY26 release and call, 9 Nov 2026; company filings; Penmark Research model

Exhibit 57: Space Systems grows 30% in FY27E off a $1.71bn backlog and fades to 20% by FY30E
Space Systems revenue ($m)Growth y/y (%) (right)$0m$500m$1,000m$1,500m$2,000m20406080100FY25AFY26EFY27EFY28EFY29EFY30EActualEstimates

Source: Penmark Research model; management long-run bar about 20% (Q3 FY26 call)

Exhibit 58: The $1.71bn Space Systems backlog is 1.47x the $1.17bn of revenue we model through FY27E
Backlog, 30 Sep 2026Q4 FY26E plus FY27Erevenue$1,714m$1,168m

Source: Q3 FY26 release and call; Penmark Research model ($m)

Exhibit 59: Three dated signposts test growth and margin
DateSignpostConfirmsBreaks
Feb 2027Q4 FY26 resultsRevenue at or above $280m; backlog above $3.6bnBacklog falls; growth guided below 20%
FY27 budget cycleGolden Dome, SDA Tranche 3 and 4 awardsBacklog adds (+5pp a year, $0.21)Delayed awards (−$0.13)
Q4 FY26 to Q4 FY27Mynaric and platform marginSegment margin toward 36%Stalls near 32% (−$0.66)

Source: Penmark Research model; Q3 FY26 call, 9 Nov 2026

PART 3 · THE THESIS · 12 WHAT THE PRICE IMPLIES

At $54.97 the market pays 4.0x our probability-weighted $13.83; even the 12-month bull target of $28.73 is 47.7% below it

THESIS CHAPTER 12 · RESTS ON DRIVERS A AND DThe price needs 14.6% growth forever or a cost of equity below the risk-free rate; none of our scenarios gets within 47% of it.

What the market believes

Street targets run from $58 to $150 with a mean of $100.25. The price implies a beta of −0.08, a cost of equity of 4.5% against a 4.9% risk-free rate. Debates 1 to 4 explain $14.07 of the $42.17 gap.

What it is worth

Standalone DCF is $11.11; adding Iridium gives $12.80 in the base case. The probability-weighted value is $13.83 and the 12-month target $15.85, a −71.2% price return, Sell. The EV/sales cross-check gives $16.88, 31.9% above the DCF.

Exhibit 60: Four sources agree that the price asks for far more than any single input can deliver
SourceEvidenceRead-through
Model reverse DCFPrice needs 14.6% terminal growth, or a cost of equity of 4.5%, or +37.3pp of Space Systems growth every year to FY40ENo plausible single input closes the gap
PeersRKLB 44.0x trailing sales vs 3.9x peer median; EV/sales per point of growth 0.84x vs 0.15xPremium of 11x, on 52.5% growth vs 44.1%
Equity issuance$2.4bn raised in Q3; period-end common shares 639.2m vs 543.6m at 31 Dec 2025; diluted standalone 700.9mWeighted diluted shares rise 41% from FY24A to FY27E (495.9m to 700.9m)
Street18 of 22 Buy, none Sell; mean target $100.25, low $58Street values the optionality; we value the cash flows

Source: Penmark Research model; MarketBeat and S&P Global, Nov 2026

Exhibit 61: Iridium’s multiple moves Rocket Lab’s value from $11.13 to $15.30 a share across 10.0x to 16.2x
$0$5$10$15$2010.0x bear12.5x base16.2x deal multiple$11.13$12.80$15.30

Source: Penmark Research model, 10 Nov 2026; other inputs at base

Iridium is the one place the market view is closeApplying the 16.2x deal multiple to CY27E OEBITDA lifts value to $15.30 a share, +$2.50, but implies $9.0bn of enterprise value against the $8.0bn paid; at the $8.0bn paid (14.3x) a straight-line read of the sensitivity gives about +$1.25. The base deal nets $1.88bn to Rocket Lab holders.
The dilution is in the numberThe Q3 ATM raised about $2.4bn at roughly $65 a share, far above our value, and lifted value per share by $1.58. New Iridium shares add 43.6m, taking the diluted count to 744.5m.
Exhibit 62: Three signposts that would move value toward, or away from, the price
DateSignpostConfirmsBreaks
Mid-2027Iridium closeValued at 16.2x on CY27E OEBITDA, +$2.50Approval slips; deal fails (10% probability)
2027EMSS renewal at IridiumSame rate holdsLower rate; Iridium at 10.0x, −$1.66
Each quarterWeekly sector tapeStock tracks UFOStock decouples from UFO and earnings

Source: Penmark Research model; Iridium 8-K, 20 Oct 2026

PART 4 · THE NUMBERS · 13 TRACK RECORD AND QUALITY OF REPORTED NUMBERS

Gross margin rose from −3.0% to 34.4% in four years, but every year burned cash and stock pay ran at 12% of FY25A revenue

Exhibit 63: GAAP gross margin fell to 33.6% in Q3 FY26 from 38.2% in Q1, still above 27.8% in Q4 FY24
27.530.032.535.037.540.04Q241Q252Q253Q254Q251Q262Q263Q2633.6

Source: Company income statements; Penmark calculation

Exhibit 64: Revenue beat the guide midpoint in all eight quarters, by 4.0% in Q3 FY26
024684Q241Q252Q253Q254Q251Q262Q263Q261.82.17.03.42.74.10.74.0

Source: Company releases and call guidance; Penmark calculation

Exhibit 65: Revenue grew 9.7x in four years; free cash flow has been negative in each of them
Five-year recordFY21AFY22AFY23AFY24AFY25A
Revenue ($m)62211245436602
Growth–239.0%15.9%78.3%38.0%
Gross margin−3.0%9.0%21.0%26.6%34.4%
Operating margin−164%−64%−73%−44%−38%
Stock-based compensation ($m)3356535771
SBC, % of revenue52.3%26.4%21.9%13.0%11.8%
Free cash flow ($m)−97−149−154−116−322
FCF, % of revenue−157%−71%−63%−27%−53%

Source: Company 10-K and 10-Q statements; Penmark Research calculation, FY21A to FY25A

Exhibit 66: Adjusted EBITDA flatters Q3 FY26 by $39m; $21.3m is a one-off deal cost, $18.3m recurs
Q3 FY26 lineGAAPAdjustedWhat the gap is
EBITDA ($m)−57.5−18.0$39.4m, mainly Iridium deal costs of $21.3m and stock compensation of $18.3m
Gross margin33.6%38.4%Non-GAAP removes stock compensation and amortisation; guide was 35-37% non-GAAP
Free cash flow ($m)−23.9n.a.Operating cash flow $7.2m less capex $31.1m; deposits rose to $423.6m
Net interest and other ($m)3.028.6 interestA $27.3m loss on extinguishing the 2029 convertible notes offsets $28.6m of interest income

Source: Q3 FY26 release and call, 9 Nov 2026; Penmark Research model

Accounting choices that matter for Rocket LabCustomer deposits flatter company-definition free cash flow: FY26E is −$241m with them and −$439m without. Our valuation counts stock compensation as a cash cost and excludes deposit inflows.
Share count is the largest quality issueWeighted diluted shares rose from 495.9m in FY24A to 652.3m in Q3 FY26 and 681m basic including preferred is guided for Q4. EPS of −$0.12 in Q3 FY26 is therefore spread over 23% more weighted shares than in Q3 FY25.
PART 4 · THE NUMBERS · 14 FORECASTS

Q4 FY26E revenue of $280m sits at the guide midpoint; FY27E of $1,324.6m is 0.4% below consensus

Every Q4 guided line sits inside its range, and our FY27E revenue is 0.4% below the Street. The forecast gap that matters is EPS: FY27E loss of $0.06 against consensus of $0.09, because we count interest on $4.7bn of cash.

Exhibit 67: The revenue equation: launches times price, plus Space Systems growth, takes gross margin from 35.5% in FY26E to 32.0% in FY27E, 34.6% in FY29E and 36.9% in FY30E
Driver path, US$m unless statedFY26EFY27EFY28EFY29EFY30E
Electron and HASTE launches2530333638
Revenue per launch ($m)9.610.010.410.811.2
Neutron launches01358
Space Systems growth84.4%30.0%25.0%22.0%20.0%
Group revenue9821,3251,7342,1792,718
Gross margin35.5%32.0%32.3%34.6%36.9%
EBITDA−180−68132329558
Capex−124−160−150−142−163

Source: Penmark Research model; FY26E includes 9M FY26 actuals

Exhibit 68: All six guided Q4 FY26 lines are inside their ranges in the model
Q4 FY26 guideRangeModelPosition
Revenue ($m)270 to 290280.0Midpoint
GAAP gross margin34% to 36%35.0%Midpoint
GAAP operating expenses ($m)162 to 168165.0Midpoint
Adjusted EBITDA ($m)−20 to −14−17.0Midpoint
Net interest income ($m)4545.0On guide
Stock-based compensation ($m)17 to 1918.0Midpoint

Source: Q3 FY26 release and call, 9 Nov 2026; Penmark Research model

Exhibit 69: Penmark against consensus: four gaps are explained by timing or cash interest
LinePenmarkConsensusGapReason for the gap
Revenue Q4 FY26E ($m)280.0266.4+5.1%We use the guide midpoint; consensus sits below the guided range
Revenue FY26E ($m)982.3959.2+2.4%9M actual $702.2m plus Q4 guide; consensus predates the print
Revenue FY27E ($m)1,324.61,330.0−0.4%Space Systems growth of 30% is offset by a single Neutron flight
EPS FY26E ($)−0.31−0.27−13.0%Q3 deal costs of $21.3m and a $27.3m loss on retiring the 2029 notes
EPS FY27E ($)−0.06−0.09+35.1%Interest on $4.7bn cash against Neutron losses; consensus predates print

Source: Consensus: S&P Global via StockAnalysis and Yahoo Finance, pre-print; Penmark Research model

Costs, cash and the balance sheetNon-Neutron R&D and SG&A scale with revenue; Neutron carries a fixed programme cost of $140m in FY27E plus 4% SG&A. Total operating costs of $591m in FY27E sit below FY26E’s $609m and Q4’s $660m run rate because Neutron R&D shifts into inventory after qualification; this is our most exposed cost assumption. Capex is $160m in FY27E and $150m in FY28E. Customer deposits are 35% of FY27E revenue. Cash falls from $4.68bn to $1.95bn when the Iridium cash leaves in mid-2027.
Where we differ from managementManagement cites 50%+ non-GAAP gross margin for Neutron at scale; we use 45% GAAP because there is no reuse history and Electron took about six years to reach about 40%. Management’s Space Systems bar is about 20% long run; we fade to 20% by FY30E.
PART 4 · THE NUMBERS · 15 VALUATION

A DCF gives $11.11 and an Iridium-inclusive base of $12.80; the EV/sales cross-check gives $16.88, 31.9% higher

We value Rocket Lab on a DCF to FY40E, plus Iridium at EV/OEBITDA weighted by a 90% close probability. Earnings are negative until FY28E, so P/E and EV/EBITDA are not usable. Listed peers are sub-scale and loss-making, so EV/sales against growth-adjusted peers is a cross-check, not the anchor. The 31.9% gap between the methods comes from the peer multiple: peers trade on sentiment, not on a reusable medium-lift ramp.

Exhibit 70: Standalone enterprise value is $2.9bn; $4.7bn of net cash and deals lifts equity to $7.7bn
$0m$2,000m$4,000m$6,000m$8,000m$10,000mPV cashflowsPVterminal valueEnterprisevalueCash andinvestmentsCollaredforwardDebt andleasesCustomerdepositsEquityvalue$1,908m+$1,021m$2,929m+$4,704m+$474m−$16m−$424m$7,667m

Source: Penmark Research model, valued 30 Sep 2026 ($m)

Exhibit 71: Probability-weighted value is $13.83; the price is 4.0x that
$0$20$40$60$8.05$12.80$25.06Bear30%Base50%Bull20%Weighted $13.83Price $54.97

Source: Penmark Research model, 10 Nov 2026

Exhibit 72: Value per share stays between $11.95 and $14.10 across a 4-point cost of equity range
$13.96$13.99$14.02$14.06$14.10$13.32$13.33$13.35$13.37$13.39$12.78$12.79$12.80$12.81$12.82$12.33$12.34$12.34$12.34$12.35$11.95$11.95$11.95$11.95$11.95Terminal growth2.0%2.5%3.0%3.5%4.0%Cost of equity12.65%13.65%14.65%15.65%16.65%

Source: Penmark Research model, base case, $ per share

Exhibit 73: Neutron margin and Space Systems growth move value by $2.31 across the grid
$11.75$11.96$12.22$12.54$12.91$12.03$12.25$12.51$12.82$13.20$12.32$12.54$12.80$13.11$13.48$12.61$12.83$13.08$13.40$13.77$12.89$13.11$13.37$13.68$14.06Space Systems growth shift-4pp-2pp0+2pp+4ppNeutron mature gross margin35%40%45%50%55%

Source: Penmark Research model, $ per share

Exhibit 74: The cross-check peers trade at 3.9x sales; Rocket Lab at 44.0x is 11x the median on similar growth
CompanyPrice ($)EV/TTM salesTTM growthPer point of growth
Redwire (RDW)8.113.00x63.1%0.048x
Intuitive Machines (LUNR)12.063.93x116.9%0.034x
Planet Labs (PL)14.4112.60x44.1%0.286x
Kratos (KTOS)37.803.83x25.5%0.150x
Voyager (VOYG)27.919.81x10.6%0.923x
Peer median3.93x44.1%0.150x
Rocket Lab (RKLB)54.9744.00x52.5%0.838x

Source: Prices, 9 Nov 2026; company 10-Q revenue, TTM to calendar Q2 2026; Penmark Research model

Key assumptions and whyRisk-free rate 4.86% (10-year Treasury, 6 Nov 2026); equity risk premium 4.24%; beta 2.31 from RKLB’s own regression, giving a cost of equity of 14.65%. Terminal growth 3.0% with 15% return on new capital; terminal value is 34.9% of enterprise value. Tax is 25% after $840.9m of federal NOLs.
PART 4 · THE NUMBERS · 15 VALUATION, CONTINUED

The 12-month target of $15.85 is a −71.2% price return from $54.97, well below the −10% Sell threshold

Exhibit 75: Reconciliation: $11.11 standalone becomes a $15.85 target, 3.5x below the price
Step$ per shareNote
Standalone DCF value11.11Equity $7,667m at 30 Sep 2026, rolled to $7,786m at the 10 Nov price date; 700.9m diluted shares
Add Iridium, 90% close12.80Net value $1,882.4m; 43.6m new shares; $12.99 if the deal closes
Probability-weighted value13.83Bear $8.05 (30%), base $12.80 (50%), bull $25.06 (20%)
12-month price target15.85Weighted value rolled 12 months at the 14.65% cost of equity
Price, 10 Nov 2026 intraday54.97Official close was $62.71
Price return to target−71.2%(15.85 / 54.97) − 1; below −10%, so Sell

Source: Penmark Research model, 10 Nov 2026

Exhibit 76: Probabilities rest on four Neutron date resets, two of them in 2026; every case is a Sell
CaseProbabilityValue12-month target12-month returnLinked drivers
Bear30%$8.05$9.23−83.2%B Neutron slips to 2028, 8 a year, $50m; C Space Systems +18%; D Iridium 10.0x
Base50%$12.80$14.67−73.3%B one flight FY27E, 18 a year, $60m; C +30% fading to 4%; D 12.5x
Bull20%$25.06$28.73−47.7%B 50 a year, $70m, 55%; C +45% fading to 6%; D 16.2x

Source: Penmark Research model. Probabilities are analyst judgements

Exhibit 77: To justify $54.97 the model needs 14.6% terminal growth, or a cost of equity of 4.5%
14.6%model 3.0%Implied terminal growth4.5%model 14.7%; risk-free 4.9%Implied cost of equity+37.3ppevery year FY27E-FY40ESpace Systems growth uplift25.5x4.8x at our targetEV/sales FY27E at price

Source: Penmark Research model, 10 Nov 2026

Exhibit 78: No robustness test changes the rating: the best case, sector beta 0.95, still returns −62.9%
Robustness testCost of equityValue12-month total returnRating
Base case at model cost of equity14.65%$12.80−73.3%Sell
Cost of equity −1 point13.65%$13.35−72.4%Sell
Cost of equity +1 point15.65%$12.34−74.0%Sell
Beta at high end (relevered peer median)16.28%$12.09−74.4%Sell
Sector beta 0.95 (the price-implied view)8.89%$18.75−62.9%Sell
Cross-check: EV/salesn.a.$16.88−64.8%Sell

Source: Penmark Research model, 10 Nov 2026

How the return is calculatedPrice return = target / price − 1 = −71.2%. The price at which the return crosses −10% is $17.62; the target would need to reach $49.47 at today’s price.
Result at the official closeAt the 10 Nov official close of $62.71 the return to target is −74.7%. The rating, target and scenarios are unchanged by the choice of price.
PART 4 · THE NUMBERS · 16 CATALYSTS AND 17 RISKS

Five dated events test the thesis; the largest single risk to our Sell is the Neutron 50-a-year path, at +$3.83 a share

Exhibit 79: Five dated events in the next 12 months test the thesis
Feb 2027Q4 FY26 resultsLaunch growth, FY27framingQ1 2027Neutron tank qualificationHolds or breaks 2027flightMar 2027Iridium EMSS renewalExtended to Mar 2027 atsame rateMid-2027Iridium closeAbout 44m RKLB sharesissued2027Neutron first flightEBITDA turns about 6months later

Source: Penmark Research model; Q3 FY26 call; Iridium 8-K, 20 Oct 2026

Exhibit 80: Penmark expectations against consensus for each dated event
DateEventPenmarkConsensusDebate
Feb 2027Q4 FY26 results and FY27 framingRevenue $280m; launch growth above 20%Revenue $266.4m3
Q1 2027Neutron Stage 1 tank qualificationQualifies; first flight FY27ENot published2
FY27 budget cycleGolden Dome, SDA Tranche 3 and 4 awardsBacklog adds, +$0.21Not published3
2027Neutron first flightOne revenue launch in FY27ENot published1, 2
Mid-2027Iridium close and EMSS renewal90% close; 12.5xNot published4

Source: Penmark Research model; Q3 FY26 call, 9 Nov 2026; Iridium 8-K, 20 Oct 2026

Exhibit 81: Three upside risks against our Sell and four downside risks that support it: the largest is +$3.83 a share
RiskLikelihoodValue per shareWhat it does
Against our Sell: Neutron reaches 50 launches a yearMarket-implied path+$3.83Value still $16.63, far below the price
Against our Sell: Iridium at the 16.2x deal multiple25%+$2.5016.2x applied to CY27E OEBITDA
Neutron slips again or fails on debut (Bear 1)40%−$0.27Ramp moves a year right
Competitor pricing: SpaceX, Starship, new entrants (Bear 2)25%−$0.37Neutron at $50m instead of $60m
Space Systems margin stalls at 32% (Bear 3)30%−$0.66Mynaric and platform mix dilute
Iridium EMSS renewal at a lower rate (Bear 4)30%−$1.66Iridium at 10.0x instead of 12.5x

Source: Penmark Research model, 10 Nov 2026. Likelihoods are analyst judgements

What would change the ratingThe rating moves to Hold only if the target rises above $49.47 at today’s price, or the price falls below $17.62 at our target. At the current $54.97, no catalyst in the list closes that gap.
Other risksRegulatory approvals for Iridium (about 10% chance of no close); key-person risk in Peter Beck as founder, CEO and Chair; US budget timing under a continuing resolution (−$0.13).
PART 5 · APPENDIX · 18 OWNERSHIP AND TRADING

Insiders sold $117m in four months with no purchases, and 18 of 22 analysts rate the stock Buy

Exhibit 82: Directors and officers own 8.4%; Vanguard holds 9.6%, Khosla 6.1% and BlackRock 5.2%
Directors and officersVanguardKhosla entitiesBlackRockOther holdersDisclosed holders, % ofshares70.78.49.66.15.2

Source: FY2025 proxy statement, 6 Apr 2026 (directors and officers, Khosla, BlackRock); Vanguard from 13F, 30 Jun 2026

Exhibit 83: 18 of 22 Street ratings are Buy and none is Sell; the low target is $58
Buy / Strong BuyHoldStreet ratings184

Source: MarketBeat, 10 Nov 2026

Exhibit 84: Insiders sold about $117m in four months to 2 Nov 2026; Peter Beck sold $82.1m
Peter BeckAdam SpiceFrank KleinBrad ClevengerArjun Kampani$82.1m$26.8m$5.5m$1.1m$0.9m

Source: Form 4 filings, 8 Jul to 2 Nov 2026; no open-market purchases

Exhibit 85: Short interest is 45.3m shares, 1.96 days to cover, little changed since July
0102030405030 Jun15 Jul31 Jul14 Aug31 Aug15 Sep30 Sep15 Oct42.645.945.844.445.443.544.445.3

Source: FINRA short interest, 30 Jun to 15 Oct 2026

Exhibit 86: The four largest disclosed holders own 29.3% of shares, led by Vanguard at 9.6%
HolderShares% of sharesBasis
Directors and officers52.4m8.4%FY2025 proxy, 6 Apr 2026
Khosla-affiliated entities34.9m6.1%FY2025 proxy
BlackRock30.2m5.2%FY2025 proxy
Vanguard57.4m9.6% of 598.4m13F, 30 Jun 2026

Source: FY2025 proxy statement (6 Apr 2026); Vanguard from 13F filings, period 30 Jun 2026

Exhibit 87: Five target cuts since the Neutron delay: the lowest Street target is still $58
BrokerTarget changeDate
Piper Sandler$83 to $5810 Nov 2026
Cantor Fitzgerald$122 to $11110 Nov 2026
Citizens$130 to $90After 14 Oct 2026
KeyBanc$135 to $100After 14 Oct 2026
BofA$110 to $100After 14 Oct 2026

Source: MarketBeat, 9-10 Nov 2026; Penmark Research model

Trading and liquidityThe latest short-interest settlement (15 Oct 2026) is 45.3m shares, 1.96 days to cover, up 1.9% on 30 Sep. The CFO sold 44,656 shares on 2 Nov 2026 at $54.07 to $54.78 under a 10b5-1 plan and still holds 1,155,967 shares directly. Street targets: low $58, mean $100.25, median $102.50, high $150.
PART 5 · APPENDIX · 19 FINANCIAL MODEL

Net income turns positive in FY28E at $81m and reaches $472m in FY30E; EPS passes $0.67

Exhibit 88: Annual statements: losses to FY27E, then operating leverage as Neutron and Space Systems scale
Income statement and cash flow, US$mFY24AFY25AFY26EFY27EFY28EFY29EFY30E
Revenue4366029821,3251,7342,1792,718
Growth–38.0%63.2%34.8%30.9%25.6%24.7%
Gross profit1162073494245607541,004
EBITDA−156−185−180−68132329558
EBIT−190−229−260−16711187395
Net income−190−198−196−4181257472
EPS ($)−0.38−0.37−0.31−0.060.120.370.67
Operating cash flow−49−166−117167398611881
Capex−67−156−124−160−150−142−163
Free cash flow, company definition−116−322−2417248469718
FCF excluding deposits–−301−439−63104314529
Ending cash and investments4191,1044,6821,9532,2012,6703,388

Source: Company filings (A); Penmark Research model (E). Statements are standalone; Iridium is held at cost from mid-2027. Shaded = estimates

Exhibit 89: Margins reach 20.6% EBITDA in FY30E from −18.3% in FY26E; shares stay near 700m
Margins and per-share dataFY24AFY25AFY26EFY27EFY28EFY29EFY30E
Gross margin26.6%34.4%35.5%32.0%32.3%34.6%36.9%
EBITDA margin−35.8%−30.7%−18.3%−5.1%7.6%15.1%20.6%
EBIT margin−43.5%−38.0%−26.4%−12.6%0.6%8.6%14.6%
Net margin−43.6%−32.9%−19.9%−3.1%4.6%11.8%17.4%
Weighted diluted shares (m)496531642701701701701
FCF per share ($)−0.23−0.61−0.380.010.350.671.02
Dividend per share ($)0.000.000.000.000.000.000.00
P/E at $54.97n.m.n.m.n.m.n.m.478x150x82x

Source: Penmark Research model. P/E at the model price of $54.97 on EPS of $0.115, $0.367 and $0.673

Exhibit 90: Cash of $4.68bn in FY26E is the cushion; it falls to $1.95bn after Iridium in FY27E
Balance sheet and operating driversFY24AFY25AFY26EFY27EFY28EFY29EFY30E
Cash and investments, US$m418.91,103.74,682.31,952.92,200.62,669.73,387.8
Customer deposits, US$m216.2195.4392.9463.6607.1762.6951.2
Stockholders equity, US$m382.51,721.95,798.65,850.36,026.36,381.66,962.4
Electron and HASTE launches16212530333638
Neutron launches0001358
Space Systems revenue, US$m–402.8743.0965.91,207.31,472.91,767.5
Space Systems growth––84.4%30.0%25.0%22.0%20.0%

Source: Company filings (A); Penmark Research model (E). Equity and cash are standalone; Iridium at cost

Beyond FY30EThe forecast runs to FY40E; this page shows FY30E. By FY40E revenue is $6.5bn with operating income of $1,352m, and terminal growth is 3.0%. Growth fades from 63% in FY26E to 4% in FY40E.
How FY26E and the share count are builtFY26E combines 9M actuals ($702.2m revenue) with the Q4 guide midpoint of $280m. FY24A cash of $419m is cash plus investments excluding the balance-sheet restricted cash. EPS is on weighted diluted shares; the FY28E+ share count is the standalone 700.9m and excludes the 43.6m Iridium consideration shares.
PART 5 · APPENDIX · 19 FINANCIAL MODEL, QUARTERS

Revenue has risen for six straight quarters to $267.8m; gross margin has eased to 33.6% from 38.2% in Q1 FY26

Exhibit 91: Eight reported quarters: revenue doubled from $132.4m in Q4 FY24 to $267.8m in Q3 FY26
Quarterly income statement and cash flow, US$mQ4 FY24Q1 FY25Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26
Revenue132.4122.6144.5155.1179.7200.3234.1267.8
Growth y/y––––36%63%62%73%
Launch Services42.435.646.640.975.963.744.653.1
Space Systems90.087.097.9114.2103.8136.7189.5214.8
Gross profit36.835.246.457.368.276.584.690.1
Gross margin27.8%28.8%32.1%37.0%38.0%38.2%36.1%33.6%
EBITDA−42.4−50.5−50.9−47.2−36.3−41.0−36.6−57.5
Net income−52.3−60.6−66.4−18.3−52.9−45.0−49.3−79.7
Operating cash flow−2.4−54.2−23.2−23.5−64.5−50.3−84.17.2
Free cash flow−23.9−82.9−55.3−69.4−114.2−77.4−110.1−23.9

Source: Company 10-K and 10-Q statements and Q3 FY26 release; Q4 = full year less nine months; Penmark Research model

Exhibit 92: Backlog rose to $3.57bn and diluted shares to 652.3m in the same eight quarters
Segment and KPI detailQ4 FY24Q1 FY25Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26
Backlog ($m)–1,067–1,1001,8502,2002,3603,570
Headcount–––2,6022,645–3,2173,259
Diluted shares (m)–505.6515.1528.7–605.4629.7652.3

Source: Company releases and filings KPI; blanks are not reported

Exhibit 93: The single forecast quarter, Q4 FY26E, sits at the midpoint of every guided line
Q4 FY26E against guidance, US$mGuide lowGuide highModelPosition
Revenue270290280.0Midpoint
GAAP gross margin34%36%35.0%Midpoint
GAAP operating expenses162168165.0Midpoint
Adjusted EBITDA−20−14−17.0Midpoint
Net income (model)––−22.0Not guided
EBITDA (model)––−44.5Not guided

Source: Q3 FY26 release and call, 9 Nov 2026; Penmark Research model

Exhibit 94: Revenue landed above the guided range in four of eight quarters and never below it
QuarterGuided revenue ($m)Actual ($m)Versus the range
Q4 FY24125 to 135132.4Inside
Q1 FY25117 to 123122.6Inside
Q2 FY25130 to 140144.5Above
Q3 FY25145 to 155155.1Above
Q4 FY25170 to 180179.7Inside
Q1 FY26185 to 200200.3Above
Q2 FY26225 to 240234.1Inside
Q3 FY26250 to 265267.8Above

Source: Company releases and Q3 FY26 call; guidance ranges as issued each quarter

Quarterly patternLaunch revenue is lumpy: $75.9m in Q4 FY25 and $44.6m in Q2 FY26, with launch timing the main swing. Space Systems has grown in every quarter shown except Q4 FY25, and was 80% of Q3 FY26 revenue. We model no further quarters; guidance covers one quarter only and the model moves to annual forecasts.
PART 5 · APPENDIX · 20 REFERENCE

Reference: Q3 FY26 adjusted EBITDA of −$18.0m is −$79.7m of reported net income

Exhibit 95: Reconciliation from adjusted EBITDA to reported net income, Q3 FY26
Adjusted to reported, US$mQ3 FY26
Adjusted EBITDA−18.0
Less: Iridium deal costs(21.3)
Less: stock-based compensation(18.3)
EBITDA, operating income plus D&A−57.5
Less: depreciation and amortisation(21.7)
Operating income, reported−79.2
Net interest and other income3.0
Net income, reported (after tax $3.5m)−79.7

Source: Q3 FY26 release, 9 Nov 2026; Penmark Research model

Glossary

  • Electron, HASTE. Rocket Lab’s small orbital rocket and its suborbital hypersonic-test version
  • Neutron. Larger reusable rocket, up to 13,000kg to low orbit; first flight no earlier than 2027
  • Space Systems. Segment building satellites, solar panels, optics and components
  • Backlog. Contracted revenue not yet recognised: $3.57bn at 30 Sep 2026
  • ATM. At-the-market programme: shares sold gradually into the market
  • 1-3-5. Management’s Neutron cadence: 1, 3 then 5 launches in successive years

Methodology note

Space Systems earns revenue from multi-year projects held in backlog; Launch earns a price per flight; Iridium would add service revenue. Value is a DCF of standalone Rocket Lab to FY40E plus Iridium at EV/OEBITDA, weighted by a 90% close probability. EV/sales is a cross-check only. P/E and EV/EBITDA are not used because earnings are negative to FY27E. Price is a 10 Nov 2026 intraday quote of $54.97; the official close was $62.71. Reporting currency is US dollars.

Data sources

  • Company 10-K, 10-Q and Q3 FY26 release and call, as of 9 Nov 2026
  • FY2025 proxy statement, as of 6 Apr 2026
  • Form 4, 13F and FINRA short interest, as of 15 Oct to 2 Nov 2026
  • Yahoo Finance prices and consensus, as of 10 Nov 2026
  • MarketBeat, S&P Global via StockAnalysis, as of 6 to 10 Nov 2026
  • Satellite Industry Association, US Space Force, public launch logs, as of 2025 to Nov 2026
Exhibit 96: Ratio and metric definitions
MeasureDefinitionSource
Price return12-month target / price − 1, excluding dividends; sets the ratingPenmark rule
Probability-weighted value30% bear, 50% base, 20% bullModel, Scenarios
12-month targetWeighted value rolled 12 months at the 14.65% cost of equityModel, Summary
Free cash flow, companyOperating cash flow less capex, including customer depositsModel, Financials
EV/TTM salesEnterprise value / trailing 12-month revenue to calendar Q2 2026Model, Peers

Source: Penmark Research model

PART 5 · APPENDIX · 21 DISCLOSURES

Analyst certification and important disclosures

Ratings

Ratings are based on the upside from the share price to our 12-month price target, excluding dividends. The price target is weighted across bull, base and bear scenarios.

BuyUpside to price target above +10%
HoldUpside to price target from −10% to +10%, inclusive
SellUpside to price target below −10%

We review ratings at each set of results and whenever the facts change materially. A share price can move outside its band before the rating changes, and targets may not be reached.

Analyst certification

The Penmark Team certifies that (1) the views in this report accurately reflect its views about the subject company and its securities, and (2) no part of its compensation was, is or will be directly or indirectly related to the specific ratings, price targets or views in this report.

Contact

Penmark Research

Questions about our research:
research@penmarkresearch.com

All our research and coverage:
penmarkresearch.com

Basis of preparation

This report uses information publicly available up to its publication date. Share prices are closing prices on the trading day before the publication date, unless stated otherwise. Forecasts, valuations and price targets are Penmark Research’s own, and forecast periods are marked E. Sources are shown beneath each exhibit.

Valuation and price targets

Price targets are based on the valuation methods set out in each report and are weighted across bull, base and bear scenarios. The main risks to each rating and price target are described in the report. Penmark Research updates its coverage after each set of results but is not obliged to update a report at any other time.

Independence and conflicts of interest

Penmark Research is independent. It does not provide investment banking, brokerage, market-making or asset management services, does not trade securities, and does not accept payment from any company for research coverage. Companies do not see or review Penmark Research reports before publication.

No member of the Penmark Team holds a long or short position, directly or through derivatives, in the securities of any company Penmark Research covers.

Regulatory status

Penmark Research publishes general, impersonal investment research on a regular basis. It is not registered as an investment adviser with the US Securities and Exchange Commission or any state securities authority, is not a registered broker-dealer and is not a member of FINRA. Penmark Research does not give advice tailored to any person’s circumstances.

Not investment advice or an offer

This report is for information only. It is not personalised investment advice and is not an offer or solicitation to buy or sell any security or other financial instrument. It does not take into account any reader’s objectives, financial situation or needs. Readers should make their own investment decisions and seek independent professional advice where appropriate.

Forward-looking statements and risk

Forecasts, valuations and price targets are estimates based on assumptions that may prove wrong, and they may not be achieved. Opinions are current as of the publication date and may change without notice. Investing in equities involves risk, including the loss of capital. Share prices can be volatile, and past performance is not a reliable indicator of future results.

Data and sources

Company financials, operating data and filings come from company filings, earnings releases and earnings calls. Market data and any consensus estimates come from third-party sources named beneath the relevant exhibit; consensus figures from aggregators are unofficial. Penmark Research does not use other brokers’ research. Third-party data belong to their providers and may not be extracted from this report.

Accuracy and liability

Information is taken from sources believed to be reliable, but Penmark Research makes no representation or warranty as to its accuracy, completeness or timeliness. To the fullest extent permitted by law, Penmark Research accepts no liability for any loss arising from use of this report. Descriptions of litigation and regulatory matters reflect allegations and public records, not findings, unless stated. If a published report is corrected, the corrected version carries an “Updated” date at penmarkresearch.com.

Distribution and access

Penmark Research reports are available to readers of penmarkresearch.com. Downloads and programmatic access are governed by the Penmark Research subscription terms. This report is not directed at, or intended for, any person in Singapore or India, and access from those countries is blocked. It is not intended for distribution to, or use by, any person in any jurisdiction where that would be contrary to law or regulation or would subject Penmark Research to registration or licensing requirements there.

Copyright and permitted use

© Penmark Research. All rights reserved. Penmark Research is a trade name of Brightriver Labs. Readers may share a link to this report but may not copy, reproduce, redistribute, sell or use its content, including for text and data mining, without written consent. Contact: research@penmarkresearch.com.

Keep reading

Sign in to Penmark